Long-term follow-up in such diseases as psoriasis and atopic dermatitis are reinforcing the empiric impression that a ‘super ...

Belantamab mafodotin (Blenrep), pomalidomide (Pomalyst), and dexamethasone (BPd) was well tolerated and led to deep responses in patients with high-risk multiple myeloma.

The upcoming webinar will delve into the advanced applications of Next Generation Flow™ in the analysis of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). Dr. Juan Flores-Montero, a ...

Leveraging AI to help analyze and visualize data gathered from a variety of data sets enables data-driven insights and fast analysis without the high costs of talent and technology. In today's ...

HOUSTON -- Complete response (CR) rates in relapsed/refractory NPM1-mutated acute myeloid leukemia (AML) doubled historical rates in a preliminary study of an investigational menin inhibitor. A pooled ...

C4 Therapeutics, Inc. (C4T) announced promising results from the latest data on its investigational drug cemsidomide for treating multiple myeloma, showing a 50% overall response rate (ORR) at the ...